Meet the
TransMedics Team
Experience and Innovation For the Future of Organ Preservation
The TransMedics leadership team brings a wealth of experience in the fields of organ transplantation, clinical research, medical devices, and many others to our goal of improving the lives of transplant patients and their families around the world.
Dr. Waleed Hassanein founded TransMedics in 1998 to revolutionize organ transplant therapy for the treatment of end-stage lung, heart, and liver failure. Dr. Hassanein’s pioneering clinical research led to the development of an entirely new living organ preservation field for transplantation. Human organs could now be kept alive and functioning (heart beating, lung breathing, liver producing bile, etc.) outside of the human body in TransMedics’ revolutionary portable Organ Care System (OCS™) technology. Under his leadership, TransMedics has established itself as the global leader in living organ preservation and the OCS™ technology is becoming the new standard of care for solid organ transplantation. Dr. Hassanein was named as one of the top 50 Global Thinkers in Healthcare by Foreign Policy Magazine in 2015. He was the awardee of the Tribeca Disruptive Innovators Award in 2018 and was a finalist for the European Patent Office Inventor Award in 2017. Dr. Hassanein is a frequent guest speaker in national and international meetings on the future of organ preservation for transplantation. Dr. Hassanein earned his M.D. from Georgetown University School of Medicine. He completed two years of general surgery training at Georgetown University Medical Center. He then completed a three-year cardiac surgery research fellowship at the West Roxbury VA Medical Center and Brigham and Women’s Hospital in Boston. His research on ex-vivo heart perfusion for transplantation was recognized by the American Association for Thoracic Surgery in 1998.
Stephen Gordon joined TransMedics in March of 2015 and leads our finance and accounting team. He has over 20 years of experience leading financial organizations within high technology and medical device companies. During this time his areas of focus have been strategic planning, M&A integration, financial planning and analysis, and improvement in the presentation of quantitative information. Prior to joining TransMedics, Mr. Gordon was the Vice President, Financial Planning & Analysis at Analogic Corporation, a medical device and security technology company. Before joining Analogic, Mr. Gordon held various financial leadership positions at Hologic, Cytyc, Maxtor and Hewlett-Packard. Mr. Gordon earned a Bachelor’s degree in Finance and Accounting from The Wharton School at The University of Pennsylvania, and an MBA from Boston University.
Dr. Khayal joined TransMedics in 2001. Over the past 18 years Dr. Tamer Khayal assumed growing responsibilities to the current role of Chief Commercial Officer in January 2018. From 2007-2018 he was the Chief Medical Officer leading TransMedics’ global effort of building the clinical evidence, reimbursement initiatives and use model integration programs to support the PMA approvals and global commercial adoption of the Organ Care (OCS™) technology for lung, heart and liver transplantation. His patient focused approached to commercial rollout, made Dr. Khayal gain the trust and respect of the OCS™ users world-wide. Prior to joining TransMedics, Dr. Khayal served for six years as the Director of Medical Affairs for Zentiva Middle East, a pharmaceutical company, where he led clinical research, regulatory filings and clinical sales training for the company’s ME&A operations. Dr. Khayal received his MD degree from Cairo University School of Medicine and a General Certificate of Education from the University of London, England.
Anil Ranganath joins TransMedics with over 15 years of experience in the life sciences and biotechnology tools industries. Prior to joining TransMedics, Mr. Ranganath served multiple roles of increasing scope and responsibility at Waters Corporation. Most recently, Mr. Ranganath served as Vice President, Deputy General Counsel for Waters, managing legal affairs, and serving as a trusted advisor on Waters’ strategic, tactical, and operational plans. He began his legal career as an Associate at Brown Rudnick LLP, representing life sciences and biotechnology companies on corporate and intellectual property matters. Mr. Ranganath holds a Juris Doctorate from Suffolk University Law School and a Bachelor’s degree in Computer Science from Worcester Polytechnic Institute.
Nick Corcoran joins TransMedics with over 20 years of experience in global supply chain and commercial operations. Prior to joining TransMedics, Mr. Corcoran served multiple roles of increasing responsibility at Stryker Corporation. Most recently, Mr. Corcoran served as Vice President of Division Operations for Stryker Joint Replacement, managing the division’s entire supply chain, including internal manufacturing sites and external supply partners. Earlier in his career at Stryker, Mr. Corcoran served as Vice President of Division and Commercial Operations for the Spine Division, Senior Director of Division Operations, and Director of Global Sourcing. He also held a variety of Supply Chain and Operations roles at Waters Corporation and Intel Corporation. Mr. Corcoran holds a bachelor’s degree in Finance and Economics from South East Technological University and a Master’s of Business in Supply Chain Management from The Smurfit School of Business, University College Dublin.
Miriam Provost has over 24 years of experience in Medical Device Regulatory Affairs, including 13 years at the Food and Drug Administration. Prior to joining TransMedics, Dr. Provost was an internationally recognized expert in Regulatory Affairs and provided strategic guidance and tactical support for large and small medical device companies as medical device regulatory consultant. Her expertise stems from 13 years as a reviewer and manager at the Food and Drug Administration where she served in a variety of roles across the Agency, gaining broad knowledge and familiarity with all matters related to FDA policies, procedures and decision-making. Dr. Provost earned a Bachelor’s degree in Chemical Engineering from the University of Dayton and M.S. and Ph.D. degrees in Chemical Engineering from the University of Pennsylvania.
Mark Anderson joined TransMedics in March of 2006. With over 15 years of complex product development and engineering management expertise, Mr. Anderson has a proven record of bringing innovative Class II and Class III medical products to market, including organ perfusion and heart assist devices. Prior to joining TransMedics, Mr. Anderson served as R&D Manager of Software and Electrical Engineering for Teleflex Inc., where he led technical teams developing the next-generation intra-aortic balloon pump. He also held electrical and systems engineering roles developing submarine sonar systems for the Naval Undersea Warfare Center. Mr. Anderson earned a Bachelor’s degree in Electrical Engineering with a minor in Computer Science from Worcester Polytechnic Institute.
Laura joins TransMedics with over 20 years of experience leading clinical affairs teams in the conduct and execution of medical device clinical studies which have resulted in successful approvals. Before joining TransMedics, Laura served as Director of Clinical Studies at Thoratec Corporation/Abbott, specializing in their Mechanical Circulatory Support business. Laura holds a Master of Public Health from the University of Michigan and received her nursing degree from Grand Valley State University.
TransMedics Board of Directors and Observers
- James R. Tobin
Chairman of TransMedics Board - Edward M. Basile
- Thomas J. Gunderson
- Merilee Raines
- Waleed Hassanein, MD
President and Chief Executive Officer - Edwin M. Kania, Jr.
- David Weill, M.D.
- Stephanie Lovell